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R
apid advances in genetic science and technology 
have led to the wide availability of genetic test‑ 
 ing for a broad range of conditions. The compan‑
ies that develop and market genetic testing technologies 
have started to promote their products aggressively, even 
though  their  predictive  value  is  often  in  doubt.  Some 
worry  that  insurers,  employers,  and  financial  institu‑
tions might introduce genetic testing or use information 
about an individual’s genetic predisposition to deny ac‑
cess to specific services or to charge exorbitant rates to 
insure individuals in specific risk categories. 
The background to the adoption of the Genetic Informa‑
tion Nondiscrimination Act (GINA) in the United States 
has important lessons for Canada, especially in view of 
the increasing trend toward privatized services within the 
Canadian public health care system. When the US legisla‑
tion was finally adopted in May 2008, observers rejoiced 
that “[a]t last, the United States has a federal law that pro‑
tects consumers from discrimination by health insurers 
and employers on the basis of genetic information.”1 GINA 
is the culmination of a long process that began in 1995 
when federal lawmakers first introduced the legislation. 
In the interim, more than 45 American states had passed 
their own genetic nondiscrimination laws.2
Such  a  high  level  of  legislative  activity  indicates  a 
deep and abiding public concern about the issue of gen‑
etic discrimination. Yet the same level of angst has yet to 
make its way north. Although a recent Canadian study 
reports on perceptions of genetic discrimination with re‑
gard to people at risk for Huntington’s disease,3 discus‑
sion of the general issue in Canada has been limited and 
is focused primarily on discrimination in the context of 
life insurance.4 More significantly, there is no legislation 
comparable to GINA at either the federal or the prov‑
incial/territorial level in Canada. Does the absence of 
such legislation mean that Canadians are at higher risk 
of genetic discrimination than Americans? Does Canada 
require similar legislation? 
The US experience 
Despite widespread concern in the United States about 
discrimination on the basis of genetic test results, there 
were few documented examples of its occurrence, and no 
evidence that genetic testing for employment or health 
insurance purposes was common.2,5 Greely5 maintains 
that market conditions were such that there was rela‑
tively little incentive for insurers to use genetic testing to 
discriminate. Before pursuing such a course, an insurer 
would need to be confident that the financial benefits of 
introducing genetic testing to differentiate people would 
significantly outweigh the costs. As for employers, the 
potential costs of negative publicity, employee dissatis‑
faction, and resulting litigation would be significant if it 
were demonstrated that an employer had used an indi‑
vidual’s genetic testing results as a basis to deny access to 
employment or to health insurance coverage.   
Clearly, US lawmakers were unconvinced that market 
disincentives alone would protect consumers; thus the 
perceived triumph of GINA. Although market forces are 
no more protective in Canada than they are in the United 
States, Canadians appear to be less concerned about this 
issue than their neighbours to the south, and there is 
currently little pressure to adopt similar legislation in 
Canada. To appreciate why this issue has played out so 
differently on either side of the border, it is important to 
understand some details about GINA. 
First, GINA’s purview is confined to health insurance 
and employment, and does not cover life insurance, dis‑
ability  insurance,  or  long‑term  care  insurance.  GINA 
prohibits health insurers from requesting or requiring 
individuals to undergo genetic tests and from using gen‑
etic information to determine eligibility for coverage or 
to set premiums. In a similar vein, it prohibits employ‑
ers from using genetic information to make employment decisions with regard to hiring, firing, job assignments, 
and so forth. “Genetic information” in this context in‑
cludes not only information about an individual’s own 
genetic tests, but also genetic tests of family members (up 
to and including fourth‑degree relatives). Indeed, GINA’s 
notion of genetic information is expansive, in that it pro‑
hibits employers and health insurers from asking ques‑
tions about any manifestation of a disease or disorder in 
a family member.1,6 Thus, covered entities under GINA 
cannot ask potential clients or employees whether there 
is a family history of cystic fibrosis or Huntington’s dis‑
ease, whether they have ever been tested for breast or 
colorectal cancer, or whether anyone in the family suf‑
fers from heart disease.1 
GINA targets health insurers and employers specifically 
because the majority (around 60%) of Americans receive 
their basic health insurance through their employers. To 
be denied employment on the basis of a genetic predispos‑
ition could effectively preclude people and their dependents 
from access to basic health care coverage. Thus, one read‑
ing of GINA on its adoption in 2008 was that it was a tacit 
admission on the part of US legislators that health care is a 
public good that cannot be entrusted to the vagaries of mar‑
ket forces alone. This explains both GINA’s somewhat ex‑
pansive notion of genetic information on the one hand and 
the careful exclusion of life, disability, and long‑term care 
insurers from its remit on the other. Indeed, the reason a 
genetic discrimination statute made its way through Con‑
gress while general health care reform was stalled for years 
may have much to do with who feels most at risk of genetic 
discrimination. It was those who had access to health care 
and employment in the US who were most likely to access 
genetic services. This segment of the population is clearly 
more vocal, better connected, and more likely to exert a dir‑
ect influence on the legislative process than those who are 
unemployed and without health insurance.7,8 
Lessons for Canada
Canada has long considered basic health care to be a 
public good, and all Canadian residents enjoy access to it. 
This is the main reason Canadians in general have dem‑
onstrated less anxiety about genetic discrimination than 
their American neighbours; it is also the reason there is 
currently no urgent need for GINA‑type legislation fo‑
cused on health insurance in Canada. That being said, 
the protections Canadians enjoy are contingent on the 
strength of their publicly funded health care system and 
the continuing availability of a broad range of services. 
One key criticism of GINA is that it applies only to in‑
dividuals who are asymptomatic and who have a genetic 
risk factor, but does not prohibit adverse action vis‑à‑vis 
conditions that are already manifest or non‑genetic risk 
factors. “The essence of genetic discrimination in health 
insurance,” says one commentator,2 “has nothing to do 
with genetics, it involves health policy. The best way to 
resolve the problem would be to enact laws based on the 
principle  that  individuals  who  are  sick  or  more  likely 
to get sick (from whatever cause) are entitled to health 
coverage without regard to their current health status 
or risk.” Another remarks, “The law itself may be more 
an artifact of a fundamentally flawed health care system 
than a one‑size‑fits‑all solution to the problem of genetic 
discrimination.”8  
The current health care reform initiative in the United 
States will certainly address part of this criticism.9 (For 
general  information  about  the  US  health  reform  pro‑
gram, see http://www.healthreform.gov/.) It will improve 
access to health insurance, for example, by offering tax 
credits for insurance premiums based on income and by 
prohibiting insurers from denying coverage because of 
pre‑existing conditions or risk factors. To some degree, 
this could offer to those with any form of health risk what 
GINA offers only to those at genetic risk. It remains to 
be seen, however, to what extent overall access to health 
care will be improved and how important the additional 
protection offered by GINA will remain.
The adoption of GINA and the policy debate surround‑
ing it in the US health care system should be taken ser‑
iously in Canada. In the absence of an adequately funded 
public health care system in which accessibility is based 
on need rather than the ability to pay, there is continual 
pressure to develop various legislative and regulatory in‑
itiatives to correct serious inequities in access to health 
care. But such initiatives, as GINA shows, create their 
own inequities and challenges. 
No one argues that the Canadian health care system is 
without flaws, but on the fundamental health policy ques‑
tion of whether to treat health care as a public or a private 
good, Canada has got it right so far. Nevertheless, there 
has been much discussion of late about the need to further 
privatize health care in Canada, and mounting concern 
about the erosion of various aspects of the Canadian pub‑
lic system.10 Also, Canada’s health care system provides 
only limited coverage for pharmaceuticals, which leaves 
most funding for this growing health care expenditure to 
private insurance.11 Given the demonstrated market fail‑
ures of the US health care system,12,13 and the associated 
vulnerability of all citizens to potential genetic discrimin‑
ation,  it  is  especially  important  that  Canadians  think 
carefully about how to ensure equitable access to the full 
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spectrum of essential health care services in the face of 
continuing pressure to privatize greater portions of what 
is currently covered in the public system. 
The relative strength of our health care system not‑
withstanding, there is still a need to evaluate whether 
Canadians enjoy adequate protection against other forms 
of  genetic  discrimination.  Inappropriate  use  of  gen‑
etic technology could affect at‑risk individuals in other 
contexts,  such  as  immigration,  adoption,  or  access  to 
financial services. Life, disability, and additional health 
insurance could present other areas of concern.14 Many 
European countries with health care systems compar‑
able  to  Canada’s  have  implemented  rules  to  protect 
against genetic discrimination in these areas.15 We need 
to assess the specific roles of these goods and services, 
the nature and extent of current protections in Canada, 
and the need—if any—to impose additional restrictions. 
Extensive academic debate on the issue of genetic dis‑
crimination in Canada has yielded various suggestions 
for  further  regulatory  and  legislative  interventions.14,16 
Health  policy  scholars,  patient  advocacy  groups,  ethi‑
cists, medical researchers, the insurance industry, and 
other interested parties have raised specific issues, such 
as genetic discrimination in life insurance.17 However, it 
may be time to move from discussion to action.  
Our view is that genetic discrimination statutes fo‑
cused exclusively on health insurance are not needed in 
Canada at this time. But, to the extent that Canadians 
find it necessary to increase their individual reliance on 
other insurance schemes for essential health care, they 
will simultaneously increase their need for solid protec‑
tion  against  discrimination,  genetic  or  otherwise.18  If 
Canadians hope to keep the GINA in the bottle, they will 
need to repair and strengthen their public health care 
system rather than converting even more existing servi‑
ces from the public to private responsibility. 
Contributors: Both authors contributed equally to the preparation 
of this article.
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